Work

Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-lb337

Authors: Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna

Institutions: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, University of California, Irvine, Moffitt Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Revolution Medicines (United States), Christ Hospital, Columbia University, Huntsman Cancer Institute

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154728896

Cites:

Cited by: 6

Related to: